Three weeks of angiotensin II-induced hypertension did not significantly worsen the loss of dopaminergic neurons or the main inflammatory changes in a mouse model that overproduced human alpha-synuclein. The blood-pressure increase was clear, but the additional damage investigators expected to see was largely absent.
The experiment tested a focused question: would chronic AngII-induced hypertension potentiate the neuroinflammation and neurodegeneration associated with alpha-synuclein? The authors hypothesized that it would.
A targeted mouse test
Researchers used six-month-old C57BL/6 mice. Subcutaneous osmotic pumps delivered AngII at 1.44 mg/Kg/day for 21 days, creating the hypertensive condition in the pump cohort. A serotype-9 AAV carrying human alpha-synuclein under the synapsin 1 promoter was injected into the right substantia nigra; the left, non-injected side served as the control.
Animals were randomized for treatment, and all data collection and evaluation were performed blind to group identity. The paper reports 11 or 15 mice per experimental group, but does not give a single overall total. Results were reported as mean ± SEM and assessed with unpaired t-tests or two-way ANOVA with Bonferroni post hoc testing, as appropriate.
The pressure rose, but the brain did not show a broader hit
The hypertension model worked as intended. Mean arterial pressure, the average pressure in the arteries, rose under AngII to about 153.96 mmHg and then about 164.03 mmHg, while control pressure remained stable.
On the injected side, TH-positive neurons were reduced by about 30% on average. But the hypertensive condition did not significantly aggravate that alpha-synuclein-associated dopaminergic loss. Alpha-synuclein Ser129 phosphorylation also increased with overexpression, while hypertension did not affect it; no detectable difference in striatal TH density was reported.
The same broad pattern appeared in the glial measures. Hypertension did not alter alpha-synuclein-associated astrogliosis, whether measured by the number of GFAP-positive cells or by Gfap messenger RNA. Alpha-synuclein was associated with more IBA1-positive microglia and changes in cell size, circularity, branching and branch length, but hypertension did not modify those responses.
The inflammatory gene results were more limited than the original hypothesis suggested. Hypertension potentiated the Rela response and mildly increased Il6 under control conditions, but it did not broadly amplify the alpha-synuclein-associated responses in Il6, Tnfa, Trem2 or Tyrobp.
What the finding leaves open
That distinction matters because the study tested a particular combination of model and timing. The mice were six months old, the hypertension exposure lasted 21 days, and alpha-synuclein was produced on one side through a unilateral AAV model. The result therefore describes what happened in this short, targeted mouse experiment; it does not settle what a longer exposure or a different disease model would show.
Within those boundaries, the finding is fairly clear: AngII-induced hypertension produced a measurable rise in blood pressure but did not add substantially to the measured neuron loss, astrocyte or microglial changes, or most inflammatory gene responses. The study narrows the answer to its central question rather than showing that hypertension can never influence alpha-synuclein disease.
Paper data and sources
Original title: Angiotensin II-induced hypertension does not exacerbate α-SYNUCLEIN pathology in a mouse model of Parkinson’s disease
Authors: Silva-Llanes I, Flores-Téllez D, Arrua W et al.
Journal/Repository: Frontiers in immunology
Status: Peer-reviewed
First online: 2026-10-10
DOI: Not available
Original paper · Full text